With the exception of alopecia or toxicities related to the use of gonadotropin-releasing hormone agonists any unresolved toxicities from prior therapy greater than CTCAE grade  at time of study treatment
Patients in whom prior treatment related toxicities have not recovered to grade  or less (except for alopecia)
With the exception of alopecia, any unresolved toxicities from prior therapy greater than CTCAE Grade  at the time of starting study treatment.
Toxicities related to prior therapy must have returned to Grade  or less, except for alopecia.
Any unresolved toxicities from prior therapy greater than CTCAE grade  at the time of starting study treatment, with the exception of alopecia or neuropathy
Resolution of all clinically significant treatment-related, non-hematological toxicities, except alopecia, from any previous cancer therapy to =< grade  prior to the first dose of study treatment
All prior treatment-related toxicities must be CTCAE (version .) =< grade  (except alopecia) at the time of randomization
Resolution of all treatment-related, non-hematological toxicities, except alopecia, from any previous cancer therapy to < grade  prior to the first dose of study treatment
For participants entering cohorts C or D, prior treatment-related toxicities should have resolved to grade  or baseline (with the exception of anemia (as per inclusion criteria, alopecia, and neuropathy [=< grade  allowed])
Prior radiation or surgery must have completed at least  weeks prior to initiation of therapy and all toxicities or complications from these must have resolved to baseline or grade  prior to starting therapy (with the exception of anemia (as per inclusion criteria, alopecia, and neuropathy [=< grade  allowed])
All acute treatment-related toxicities from prior therapy must have resolved to grade =<  prior to study entry excluding alopecia
Has no prior treatment-related toxicities >Grade  (except alopecia) at the time of enrolment.
Resolution of all treatment-related toxicities, except alopecia, anemia and neuropathy, from any previous cancer therapy to ? Grade  prior to the first dose of study treatment.
Any unresolved toxicities from prior therapy greater than CTCAE Grade  at the time of starting study treatment with the exception of alopecia and Grade , prior platinum-therapy related neuropathy.
No toxicities related to prior treatment related toxicities with the exception of alopecia and neuropathy
Recovery of all chemotherapy or radiation-related toxicities to grade =< , except for alopecia and peripheral neuropathy
All acute toxicities from prior therapy with the exception of alopecia must have resolved to =< grade 
Any unresolved toxicities from prior therapy greater than CTCAE grade  at the time of starting study treatment with the exception of alopecia and grade , prior platinum-therapy related neuropathy
Patients must demonstrate resolution of all toxicities related to prior chemotherapy, endocrine therapy, or biologic therapy to grade =< , including peripheral neuropathy, with the exception of alopecia (any grade permissible)
All prior treatment-related toxicities must be CTCAE v grade =<  (except alopecia) at the time of randomization
Except for alopecia, any unresolved toxicities from prior therapy greater than CTCAE Grade  at the time of starting study treatment.
All prior treatment-related toxicities must be CTCAE v grade =<  (except alopecia) at the time of randomization
Resolution of treatment-related toxicities except alopecia
All grade >=  toxicities other than alopecia from prior therapy have resolved by the time of study commencement
With the exception of alopecia or toxicities related to the use of gonadotropinreleasing hormone agonists, any unresolved toxicities from prior therapy greater than CTCAE Grade  at the time of starting study treatment.
Unresolved toxicities from prior therapy with the exception of alopecia that have not resolved to ? Grade  at the time of starting study treatment
With the exception of alopecia, any unresolved toxicities from prior chemotherapy should be no greater than CTCAE v grade  at the time of starting study treatment
Resolution of all prior treatment-related toxicities to Grade  or less, except for Grade  fatigue or alopecia prior to CD
Must have full recovery from any toxicities from prior therapy CTCAE Grade  or less with the exception of Grade  alopecia) prior to randomization.
All acute toxicities related to prior therapy must have resolved prior to study entry, except for alopecia and mild neuropathy
All prior treatment related non-hematologic toxicities (with the exception of alopecia) must have resolved to CTCAE (Version .) ? Grade  at the time of randomization.
Failure to recover from all prior treatment-related non-hematological toxicities to ? Grade  prior to the first scheduled dose of MEDI (except for alopecia and neuropathy).